Galapagos acquires Cangenix

Wednesday, January 16, 2013

Galapagos, a mid-size clinical stage biotechnology company, has acquired Cangenix, a gene-to-structure biotech company, to add structure-based drug discovery to its Argenta service offering. Cangenix’s state-of-the-art technology will augment Argenta’s ability to design new drugs and fill a growing client need.

[Read More]